WO2026092717 - HUMANIZED ANTI-MSLN ANTIBODY AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/092717
Publication Date
07.05.2026
International Application No.
PCT/CN2025/131959
International Filing Date
31.10.2025
Title **
[English]
HUMANIZED ANTI-MSLN ANTIBODY AND USE THEREOF
[French]
ANTICORPS ANTI-MSLN HUMANISÉ ET UTILISATION DE CELUI-CI
[Chinese]
一种人源化抗 MSLN 抗体及其应用
Applicants **
SHENZHEN GENOCURY BIOTECH CO., LTD
Inventors
HUANG, Ke
LI, Yuhang
Priority Data
202411552790.4
31.10.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2210 | |
| EPO | Filing, Examination, Granting | 20281 | |
| Japan | Filing, Examination, Granting | 2709 | |
| South Korea | Filing, Examination, Granting | 3209 | |
| USA | Filing, Examination, Granting | 7140 |
Total:
35,549
Contact Us
Abstract[English]
The present invention provides a humanized anti-MSLN antibody and a use thereof. The humanized MSLN antibody of the present invention is modified to improve affinity, and the affinity thereof for binding to a human MSLN antigen is equal to or better than that of a commercially available humanized anti-MSLN antibody.[French]
La présente invention concerne un anticorps anti-MSLN humanisé et une utilisation de celui-ci. L'anticorps MSLN humanisé de la présente invention est modifié pour améliorer l'affinité, et son affinité de liaison à un antigène MSLN humain est égale ou supérieure à celle d'un anticorps anti-MSLN humanisé disponible dans le commerce.[Chinese]
本发明提供了一种人源化抗MSLN抗体及其应用。本发明的人源化MSLN抗体经过提高亲和力的改造，结合人MSLN抗原的亲和力等于或优于市售人源化抗MSLN抗体。